LeonaBio Reaches 500th Patient in Phase 3 ELAINE-3, Opening $146M Warrant Exercise Window
LONA has more than doubled off its 52-week low of $3.6 on light trading volume (0.3× avg).
Summary
LeonaBio enrolled the 500th patient in its Phase 3 ELAINE-3 trial, triggering exercisability of 23M Series A warrants that could bring up to $146.2M in capital.
Key Events · Product Development and Regulatory · LONA
-
500th Patient Enrolled in ELAINE-3
LeonaBio enrolled the 500th subject in its Phase 3 ELAINE-3 trial for lasofoxifene plus abemaciclib in ESR1-mutated metastatic breast cancer.
-
Warrant Exercise Triggered
The enrollment milestone triggers exercisability of 23,031,494 Series A Common Warrants at $6.35 per share, issued in the December 2025 private placement.
-
Potential $146.2M Capital Inflow
If exercised in full, the warrants would provide approximately $146.2 million in additional capital, versus $51.1 million cash on hand as of Q2 2026.
-
Exercise Window Through November 30, 2026
Warrants are exercisable at holders' option until the 30th day after the Initial Exercise Date, with a termination date no later than November 30, 2026.
Analysis · LONA · Life Sciences
Enrollment of the 500th subject in the pivotal Phase 3 ELAINE-3 trial for lasofoxifene in ESR1-mutated metastatic breast cancer marks more than clinical progress. It triggers exercisability of 23,031,494 Series A Common Warrants issued in the December 2025 private placement. If exercised in full at $6.35 per share, the warrants would bring approximately $146.2 million in additional capital—a substantial sum relative to the company's $51.1 million cash balance disclosed in the Q2 10-Q. The warrant exercise window opens now and runs through no later than November 30, 2026. Against a going concern warning, this milestone offers a potential financing lifeline, though exercise is at holders' option and may be cashless if a resale registration statement is unavailable.
How filings like this one have moved
In the 30 days to Sep 11, 2026, 30.2% of the 1943 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.21%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LONA was trading at $8.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $75.5M. The 52-week trading range was $3.60 to $40.80. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.